


Dysport®

Resource Catalogue



FDA-approved with more than a decade of clinical experience

FDA-approved for adult cervical dystonia in April 2009

INDICATIONS

DYSPOORT (abobotulinumtoxinA) for injection is indicated for the treatment of:

- spasticity in patients 2 years of age and older
- cervical dystonia in adults

IMPORTANT SAFETY INFORMATION

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of DYSPOORT and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

Surrounded by Support

Whether you are new to Dysport or an experienced injector, Ipsen offers a wide range of educational and support resources for you, your practice, and your patients

Get

Extensive Resources

Product information, injection simulators, eLearning modules, patient journey videos, and more at DysportHCP.com.

Trained

Peer-to-Peer Training

In person, virtual, and on-demand programs to answer questions specific to Dysport. Visit DysportHCP.com or talk to your Ipsen representative for more information.

Get

Injector Locator

Make it easy for patients, caregivers, and referring physicians to find you through our [Injector Locator](#).

Started

IPSEN CARES®

Coverage, access, reimbursement, and education support for you and your patients. Eligible, commercially insured patients may pay as little as \$0 per prescription. Visit IPSENCARES.com for more information.*

Get

Product Acquisition

Information on Dysport acquisition, coding, billing, and reimbursement. See page 16 for more information.

Going

Patient Resources

Informative brochures for patients and parents/caregivers about the management of spasticity or cervical dystonia.

*See the patient eligibility terms and conditions for the Dysport copay assistance program on page 19

 **Dysport®**
(abobotulinumtoxinA)

MENU

B.E.G.I.N. Workbook for Adult Spasticity and Cervical Dystonia

Beginning Education to Guide Injection of Neurotoxins (B.E.G.I.N.) is a workbook designed to serve as an anatomy injection reference and practical guide to using Dysport.

Anatomy & Injection Training

- Physical and Virtual Injection Simulators (S.A.D.I.E. and D.A.I.S.E.Y.)
- SynDaver™ Limbs (synthetic cadavers)
- Anatomical Injection Training Models (AITMs)
- Patient, Ultrasound & Cadaver Videos
- MasterClass Anatomy and Injection Workshops

Peer-to-Peer Education

- On-Demand Programs
- Live and Virtual Programs for Physicians and Their Staff
- MasterClass Anatomy and Injection Workshops
- See-One, Do-One Injection Training

• Important Safety Information for Dysport

Dysport Resources for Physicians

- Product Information
- Clinical Overviews and Indication Briefs
- Patient Case Study Worksheets and Injection Records
- Dosing
- Reconstitution

Preparing Your Practice With Dysport

- Office Posters and Patient Injection Records
- Electronic Health Records Guide
- Support for Product Acquisition, Coding, and Billing
- Patient Brochures

IPSEN CARES® Support for Providers

- Ipsen Resources and Support for Product Acquisition, Coding, and Billing





IPSEN CARES® for Patients

- Coverage, Reimbursement, and Copay Assistance*

*Not applicable for federally funded healthcare.

B.E.G.I.N. WORKBOOK FOR ADULT SPASTICITY

Beginning Education to Guide Injection of Neurotoxins (B.E.G.I.N.) is a workbook designed to serve as an anatomy injection reference and practical guide.





To learn more, click here to visit DysportHCP.com or scan QR code.



B.E.G.I.N. WORKBOOK FOR CERVICAL DYSTONIA

Beginning Education to Guide Injection of Neurotoxins (B.E.G.I.N.) is a workbook designed to serve as an anatomy injection reference and practical guide for cervical dystonia.



ANATOMY & INJECTION TRAINING

Injection Simulators

Take your injection practice to the next level with **S.A.D.I.E. (Spasticity Arm to Demonstrate Injection Education)** and **D.A.I.S.E.Y. (Dystonic Anatomical Injection Simulator Educating You)**. These educational tools are used to visualize and target muscles using EMG technology and help learn Dysport dosing for the recommended muscles for upper limb spasticity and cervical dystonia.


S.A.D.I.E. and D.A.I.S.E.Y.

Injection simulators for large group trainings and at major congresses



Virtual S.A.D.I.E. and D.A.I.S.E.Y.

Please note, it is recommended that you are trained by an Ipsen representative prior to accessing the virtual S.A.D.I.E. and D.A.I.S.E.Y. tools



Also available with syringe stylus for a more tactile experience
In person with an Ipsen representative



To learn more, contact your Ipsen Neuroscience Sales Representative.

EMG=electromyography.


Anatomy & Injection Training (continued)

Injection Simulators (continued)

Upper and Lower SynDaver™ Limbs


Realistic synthetic cadaver limbs, SynDaver mimics with high fidelity to reality the physical properties (e.g., resistance) of live tissues, to aid in the identification of topographical anatomic landmarks and provide a real-feel experience of an injection in the upper and lower limbs.

Contact your Ipsen representative for an expert-led guided course on relevant muscles, muscle anatomy (neuromuscular junction, end plates, insertion, origin, etc.), and functional anatomy related to spasticity.



Anatomical Injection Training Models (AITMs)

3D silicone-based anatomical models designed for demonstrating and practicing injections for upper and lower limb spasticity, as well as cervical dystonia. These models are compatible with ultrasound imaging, providing partial needle visibility. This feature allows users to practice holding the ultrasound device with their non-dominant hand while manipulating the needle with their dominant hand.



To learn more, contact your Ipsen Neuroscience Sales Representative.


Anatomy & Injection Training (continued)

Online and Downloadable Resources

Patient Treatment Journey Videos


Follow physicians and their patients with spasticity or cervical dystonia along their treatment journey with Dysport, including:

- Signs and symptoms
- Goal setting
- Injection
- Physical and occupational therapy
- Follow-up appointments
- Reinjection



Ultrasound Guidance Videos



Learn how ultrasound can be used to identify muscles for injection in the lower limb, upper limb, and head/neck areas.



Anatomy & Injection Videos

Videos using cadaver limbs to highlight anatomy of the muscles in the upper and lower limbs along with important injection technique and considerations.

Led by Dr David Porta and Dr Kimberly Heckert.



To learn more, click here to visit DysportHCP.com or scan QR code.



Anatomy & Injection Training

Dysport MasterClass

A Comprehensive, Hands-On, Injection Training Program Featuring Cadavers for Instruction and Injection Practice



Developed and led by expert faculty. Suitable for both new and experienced injectors.

Description:

Hands-on learning and injection practice with expert faculty. Includes anatomy review of the upper and lower limb, or head and neck, using cadavers, education on proper injection techniques, and considerations for approved muscles for Dysport.

Curriculum:

- Fully adaptable to audience and program needs/requirements
- Comprehensive one-day session or individual, sequenced components scheduled over time

Cost/Logistics:

- **Attendance is FREE**
- Flexibility to deliver at your institution or outside venue
- Casual attire or scrubs recommended

This presentation is a Dysport promotional program provided by Ipsen Biopharmaceuticals, Inc. Presenters are speaking on behalf of Ipsen and are being compensated for their time. MasterClass is not a continuing medical education (CME) program.

**To learn more, click here to visit
DysportHCP.com or scan QR code.**



PEER-TO-PEER EDUCATION

Faculty-Led Educational Programs and Hands-On Learning

Live educational sessions led by expert faculty are available to increase your knowledge and familiarity with Dysport. Programs are available for adult spasticity, pediatric spasticity, and cervical dystonia.



Virtual On Demands

Expert answers questions on Dysport clinical data, dosing, and patient treatment during a 30 - 45-minute pre-scheduled teleconference



MasterClass: Cadaver Anatomy and Injection Labs

Hands-on injection practice with expert faculty who review anatomy and educate on proper injection techniques and considerations for Dysport use



Group Speaker Programs

Review the efficacy, safety, duration of response, and dosing of Dysport in a webinar or in-person presentation



Dysport Dialogue

Case study-driven program focused on a facilitated discussion on goal setting, muscle and dose selection, and treatment planning for Dysport



Injection Training

See One: In-person training where a visiting expert injector observes Dysport injections and receives coaching on clinical use by a speaker

Do One: In-person training where a speaker observes an expert injector administer Dysport injections, and offers coaching on dosing, technique, and clinical use



Ultrasound Programs

Hands-on training and live demonstrations with expert faculty to enhance your Dysport injection skills through the use of ultrasound

To learn more, contact your Ipsen Neuroscience Sales Representative.

IMPORTANT SAFETY INFORMATION

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of DYSPORT and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

Contraindications

DYSPORT is contraindicated in patients with known hypersensitivity to any botulinum toxin products, cow's milk protein, or to any of the components in the formulation, or infection at the proposed injection site(s). Serious hypersensitivity reactions including anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea have been reported. If such a serious reaction occurs, discontinue DYSPORT and institute appropriate medical therapy immediately.

Warnings and Precautions

Lack of Interchangeability Between Botulinum Toxin Products

The potency Units of DYSPORT are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of DYSPORT cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

Dysphagia and Breathing Difficulties

Treatment with DYSPORT and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several weeks and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. Treatment of cervical dystonia with botulinum toxins may weaken accessory muscles of ventilation, which may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these muscles. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin.

Important Safety Information (continued)

Warnings and Precautions (continued)

Pre-existing Neuromuscular Disorders

Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of DYSPORT.

Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, vCJD, or CJD have ever been identified for licensed albumin or albumin contained in other licensed products.

Intradermal Immune Reaction

The possibility of an immune reaction when injected intradermally is unknown. The safety of DYSPORT for the treatment of hyperhidrosis has not been established. DYSPORT is approved only for intramuscular injection.

Pre-existing Conditions at the Injection Site

Caution should be exercised when DYSPORT is used where the targeted muscle shows excessive weakness or atrophy.

Adverse Reactions

- The most common adverse reactions ($\geq 4\%$) in adults with upper limb spasticity include muscular weakness; in adults with lower limb spasticity ($\geq 5\%$) include falls, muscular weakness, and pain in extremity
- The most common adverse reactions ($\geq 10\%$) in pediatric patients with upper limb spasticity include upper respiratory tract infection and pharyngitis; in pediatric patients with lower limb spasticity include nasopharyngitis, cough, and pyrexia
- The most common adverse reactions ($\geq 5\%$) in adults with cervical dystonia include muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, musculoskeletal pain, dysphonia, injection site pain, and eye disorders

Drug Interactions

Co-administration of DYSPORT and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents) should only be performed with caution because the effect of the botulinum toxin may be potentiated. Use of anticholinergic drugs after administration of DYSPORT may potentiate systemic anticholinergic effects such as blurred vision. The effect of administering different botulinum neurotoxins at the same time or within several months of each other is unknown. Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before and after administration of DYSPORT.

DYSPORT RESOURCES FOR PHYSICIANS

Clinical Trial & Product Information

Product Monographs

A product overview including molecular structure, MOA, clinical history and data from pivotal trials for the 3 indications, recommended dosing and dilution, as well as storage and handling



Clinical Overviews

Provides detailed data from pivotal clinical trials including efficacy and safety profile as well as dosing recommendations.



Indication Briefs

Indication-specific briefs that detail the study design, demographics, efficacy, and safety of Dysport studies.



To learn more, click here to visit DysportHCP.com or scan QR code.



MOA=mechanism of action.


Dysport Resources for Physicians (continued)

Clinical Trial & Product Information

Case Study Worksheets

Hypothetical patient case studies to assist with Dysport dosing scenarios for spasticity and cervical dystonia.

Dysport Dosing Scenarios: Adult Spasticity*



Upper Limb Spasticity

Lower Limb Spasticity

*Hypothetical patient and case study

INDICATIONS

• Dysport (abobotulinumtoxinA) is indicated for the treatment of:

- spasticity in patients 2 years of age and older
- cervical dystonia in adults

IMPORTANT SAFETY INFORMATION

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Healthcare providers should be aware that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include generalized muscle weakness, drooping, double vision, difficulty swallowing, difficulty breathing, difficulty speaking, difficulty lifting the head, and difficulty moving the arms and legs. These symptoms may be life threatening and there have been reports of death. The risk of symptoms is usually greatest in patients treated for spasticity, but symptoms can also occur in patients treated for dystonia and other conditions. Cautioning in these patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of distant effects have been reported at doses comparable to or less than the maximum recommended dose.

Please see additional Important Safety Information on the next page and accompanying Full Prescribing Information, including BOXED WARNING.

Dysport Dosing Scenarios: Adult Spasticity

RALPH - Left upper limb spasticity



Background and case

• 60-year-old male who experienced a right spontaneous hemorrhage 2 years ago which resulted in the development of left upper limb spasticity. He has difficulty with dressing and grooming.

• He has a right arm that is stiff, clenched, and has difficulty with fine motor skills.

• He has a right arm that is stiff, clenched, and has difficulty with fine motor skills.

Specific treatment history

- Received treatment with Botox (onabotulinumtoxinA) for the past 1 year.
- He has a right arm that is stiff, clenched, and has difficulty with fine motor skills.

Patient challenges

- Can hold items in his left hand but has difficulty using his right hand.
- He has a right arm that is stiff, clenched, and has difficulty with fine motor skills.

How would you treat Ralph?

PRINCE - Lower limb spasticity secondary to multiple sclerosis



Background and case

• 45-year-old female who has multiple sclerosis.

• She has a right leg that is stiff, clenched, and has difficulty with fine motor skills.

• She has a right leg that is stiff, clenched, and has difficulty with fine motor skills.

Specific treatment history

- Received treatment with Botox (onabotulinumtoxinA) for the past 1 year.
- She has a right leg that is stiff, clenched, and has difficulty with fine motor skills.

Patient challenges

- Difficulty with walking and other physical functions.
- She has a right leg that is stiff, clenched, and has difficulty with fine motor skills.

How would you treat Prince?

Patient Injection Records


Injection records for the 3 indications that can be uploaded to EMR systems to record Dysport doses and muscles injected at each cycle.

Dysport Injection Tracker

Total Dose: _____ Units

Dosing for upper limb spasticity between 500 Units and 1,000 Units. The maximum recommended total dose per treatment cycle is 1,000 Units. The potency units of Dysport are not interchangeable with other preparations of botulinum toxin products.

Adult Upper Limb Spasticity




Brachialis Dysport 200-400 Units	Biceps Brachii Dysport 200-400 Units
Pronator Teres Dysport 100-200 Units	Flexor Carpi Ulnaris Dysport 100-200 Units
Brachioradialis Dysport 100-200 Units	Flexor Digitorum Profundus Dysport 100-200 Units
Flexor Carpi Radialis Dysport 100-200 Units	Flexor Digitorum Superficialis Dysport 100-200 Units

Dysport Injection Tracker

Total Dose: _____ Units

Dosing for cervical dystonia. The recommended total dose is 500 Units. The maximum recommended total dose per treatment cycle is 1,000 Units. The potency units of Dysport are not interchangeable with other preparations of botulinum toxin products.

Cervical Dystonia



Sternocleidomastoid (SCM)* Dysport 50-200 Units Medium: 125 Units	Semispinalis Capitis Dysport 50-200 Units
Splenius Capitis Dysport 75-450 Units	Trapezius Dysport 50-200 Units
Longissimus Dysport 100-200 Units	Scalenus (medius and anterior) Dysport 50-200 Units
Levator Scapulae Dysport 50-200 Units	

*Located between the splenius capitis

Simultaneous BMS-guided application of Dysport may be helpful in locating active muscles.

To learn more, click here to visit DysportHCP.com or scan QR code.



EMR=electronic medical record.


Dysport Resources for Physicians (continued)

Dosing and Dilution

Dosing and Dilution Brochures

Brochures with detailed muscles and FDA-approved doses for the treatment of adult patients with spasticity or cervical dystonia.

The pediatric brochure includes a weight-based dosing slider for the appropriate dosing of Dysport for your pediatric patients aged 2 years and older.



Reconstitution and Muscle Posters

Visual aid of Dysport reconstitution and dilution instructions for your office.

Visual aid to review doses and muscles recommended for injection.



Reconstitution Practice

Vehicle vials to practice appropriate Dysport reconstitution and dilution, experience partial vacuum, and develop injection skills with SynDavers or injection pods.

Reconstituted practice vials available by request.



Vial does not contain active ingredient


To learn more, click here to visit DysportHCP.com or scan QR code.



PREPARING YOUR PRACTICE WITH DYSPORT


Acquisition, Billing & Reimbursement

The Dysport Reimbursement Resource Guide provides information on acquisition options for Dysport, billing and coding support, and an overview of IPSEN CARES® for copay and reimbursement.



Electronic Health Records Guide

A flashcard that includes a step-by-step process for office staff on how to access Dysport in their EHR database.



Office Posters and Patient Injection Records

Posters of Dysport dosing, reconstitution, and approved muscles for injection for quick reference at your office.

Injection records to help track Dysport units injected into each muscle. Billing and vial tracking information is also included to support your office staff.



To learn more, click here to visit DysportHCP.com or scan QR code.



Preparing Your Practice With Dysport (continued)

Enroll Your Practice or Find a Dysport Injector


The Dysport Injector Locator is an online search tool that is designed to make it easy for patients with spasticity or cervical dystonia, their caregivers, and referring physicians to find injectors in their area who are trained to administer Dysport.



Register to be listed at DysportHCP/Injector-Registration

Patient Brochures

Informative brochures for patients and parents/caregivers about the management of spasticity or cervical dystonia. The brochures provide questions for patients to ask their doctors, goal-setting ideas, and what can be expected with Dysport treatment.



To learn more, click here to visit DysportHCP.com or scan QR code.





IPSEN CARES

Reimbursement and IPSEN CARES® (Coverage, Access, Reimbursement & Education Support)

Acquisition, Coding, and Billing

The Dysport Reimbursement Resource Guide provides information on acquisition, coding, coverage, and billing options for Dysport, and an overview of IPSEN CARES® for copy and reimbursement.



To learn more, click here to visit
[IPSECARES.com](https://www.ipsecares.com) or scan QR code.



IPSEN CARES®

Reimbursement and IPSEN CARES® (continued)

(Coverage, Access, Reimbursement & Education Support)

Support for Eligible and Enrolled Patients Prescribed Dysport

Help patients navigate the insurance coverage process to determine out-of-pocket costs

Help with copay assistance for eligible* patients

Provide free medication to eligible† patients through the Patient Assistance Program

Help minimize delays or interruptions to treatment

Coordinate delivery of patient medication to HCP offices through specialty pharmacies

Dysport Has National Coverage Without Restrictions‡

99%

COMMERCIAL

100%

MEDICARE

99%

MEDICAID¹


‡Coverage data provided by Breakaway Partners and current as of May 2022. ¹Includes Managed and State Medicaid.

Support is only a text message away

The Text Message Program has many different types of messages to help patients stay current on their prescribed medication plan

- ✓ Refills at patient's Specialty Pharmacy
- ✓ IPSEN CARES® re-enrollment
- ✓ Changes to patient's insurance
- ✓ HCP appointment reminders

Patients can opt-in to the Text Message Program on the IPSEN CARES enrollment form



*Patient Eligibility & Terms and Conditions: Patients are not eligible for copay assistance through IPSEN CARES® if they are enrolled in any state or federally funded programs for which drug prescriptions or coverage could be paid in part or in full, including, but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, VA, DoD, or TRICARE (collectively, "Government Programs"), or where prohibited by law. Patients must be United States residents (including its territories) and enrolled in IPSEN CARES® to receive copay program benefits. Patients residing in Massachusetts or Rhode Island can only receive assistance with the cost of Ipsen products but not the cost of related medical services (injection). Patients receiving assistance through another assistance program or foundation, free trial, or other similar offer or program, are not eligible for the copay assistance program during the current enrollment year.

An annual calendar year maximum copay benefit applies. Patients may remain enrolled in copay assistance as long as eligibility criteria is met.

Patients or guardians are responsible for reporting receipt of copay savings benefit to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled through the program, as may be required. Additionally, patients or guardians may not submit any benefit provided by this program for reimbursement through a Flexible Spending Account, Health Savings Account, Health Reimbursement Account, or otherwise to a government or private payor. Ipsen reserves the right to rescind, revoke, or amend these offers without notice at any time. Ipsen and/or its copay assistance vendor are not responsible for any transactions processed under this program where Medicaid, Medicare, or Medigap payment in part or full has been applied. Claim reimbursement requests must be submitted within 180 days of treatment date. Data related to patient participation may be collected, analyzed, and shared with Ipsen for market research and other purposes related to assessing the program. Data shared with Ipsen will be de-identified, meaning it will not identify the patient. Void outside of the United States and its territories or where prohibited by law, taxed, or restricted. This program is not health insurance. No other purchase is necessary. Copay assistance cannot be sold, purchased, traded, or counterfeited. Void if reproduced.

†Patients may be eligible to receive free drug if they are experiencing financial hardship, have no insurance coverage, are US residents, and received a prescription for an on-label use of Dysport, as supported by information provided in the program application. Eligibility does not guarantee approval for participation in the program. The PAP provides Dysport product only, and does not cover the cost of previously purchased product or medical services.

IPSENCARES®

Coverage, Access, Reimbursement & Education Support

IPSEN CARES is a registered trademark of Ipsen S.A. DYSPORE is a registered trademark of Ipsen Biopharm Limited. All other trademarks are the property of their respective owners.

To learn more, click here to visit
IPSENCARES.com or scan QR code.





Dysport® (abobotulinumtoxinA) for injection, for intramuscular use 300- and 500-Unit vials.
DYSPOORT is a registered trademark of Ipsen Biopharm Limited. IPSEN CARES is a registered trademark of Ipsen S.A.
©2025 Ipsen Biopharmaceuticals, Inc. June 2025 DYS-US-006835 V3.0



Sample CMS-1500 Claim Form

Physician Office

Dysport® (abobotulinumtoxinA) and the associated services provided in a physician's office are billed on the CMS-1500 claim form or its electronic equivalent. A sample CMS-1500 claim form for billing Dysport is provided below.

The sample claim form provided below is only an example. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for the products and services rendered.

Providers should contact third-party payers for specific information regarding their coding, coverage, and payment policies.

Box 21

Enter the appropriate ICD-10-CM diagnosis code, eg, G81.11 for spastic hemiplegia affecting right dominant side (upper limb spasticity).

Code to the highest level of specificity. ICD-10-CM diagnosis codes contain 3-7 digits. It is recommended that providers verify each payer's specific coding requirements prior to injecting.

Box 23

Input the authorization number if obtained from the insurance provider.

Box 24E

For each code, insert the number corresponding to the appropriate diagnosis code in field 21.

Dysport, abobotulinumtoxinA		ICD-10-CM		ORIGINAL REF. NO.	
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Please A-L to service the below (24E))		22. PRIOR AUTHORIZATION NUMBER		23. SUBMISSION	
A. G81.11		00000000		YES NO	
1. N415054050001UN500.00		J0586 JZ		A	
2. 02 01 24 02 01 24 11		64642		A	
1. N415054050001UN500.00		J0586		A	
2. 02 01 24 02 01 24 11		J0586 JW		A	

Box 24A

In the shaded area, list the N4 qualifier, the 11-digit drug NDC#, the unit of measurement qualifier, and dosage.

Example: 15054050001UN500.00
(Note: some payers may request the NDC number be listed in box 19.)

In the non-shaded area, list the date of service.

Box 24D

Include the appropriate CPT codes to report administration procedures, eg, 64642 (chemodenervation of 1 extremity, 1-4 muscle[s], eg, for upper limb spasticity).

For Dysport, use the unique HCPCS code required by payer. Also, include appropriate modifiers as instructed by payer.

Box 24G

Report the appropriate number of units actually administered and the appropriate number of HCPCS units for Dysport J0586 (500-unit vial = 100 billing units, and 300-unit vial = 60 billing units). Please note, this example shows usage of 475-unit vials = 95 billing units and a wastage of 25-unit vials = 5 billing units.

Note: For Dysport obtained through a specialty pharmacy, no charges for the drug should be billed by the provider. However, inclusion of the HCPCS code (J0586) is recommended to designate the drug administered and number of units administered. Consult with the individual payer to determine the appropriate method of documenting and billing for drugs obtained through a specialty pharmacy.

The diagnosis and procedure codes listed on this sample claim form are provided as examples only.

Important Safety Information (Continued)

Drug Interactions

Co-administration of Dysport and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents) should only be performed with caution because the effect of the botulinum toxin may be potentiated. Use of anticholinergic drugs after administration of Dysport may potentiate systemic anticholinergic effects such as blurred vision. The effect of administering different botulinum neurotoxins at the same time or within several months of each other is unknown.

Please see additional Important Safety Information on pages 3-4 and accompanying full Prescribing Information, including BOXED WARNING.

IPSEN CARES
Coverage, Access, Reimbursement & Education Support

Dysport
(abobotulinumtoxinA)

IMPORTANT SAFETY INFORMATION

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of DYSPORT and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.